Lanyamycin, a macrolide antibiotic from Sorangium cellulosum, strain Soce 481 (Myxobacteria)

Lanyamycin (1/2), a secondary metabolite occurring as two epimers, was isolated from the myxobacterium Sorangium cellulosum, strain Soce 481. The structures of both epimers were elucidated from HRESIMS and 1D and 2D NMR data and the relative configuration of their macrolactone ring was assigned based on NOE and vicinal 1H NMR coupling constants and by calculation of a 3D model. Lanyamycin inhibited HCV infection into mammalian liver cells with an IC50 value of 11.8 µM, and exhibited a moderate cytotoxic activity against the mouse fibroblast cell line L929 and the human nasopharyngeal cell line KB3 with IC50 values of 3.1 and 1.5 μM, respectively, and also suppressed the growth of the Gram-positive bacterium Micrococcus luteus.

[1]  M. Stadler,et al.  Six Heterocyclic Metabolites from the Myxobacterium Labilithrix luteola , 2018, Molecules.

[2]  R. Müller,et al.  Natural products from myxobacteria: novel metabolites and bioactivities. , 2017, Natural product reports.

[3]  M. Stadler,et al.  Sorazolons, Carbazole Alkaloids from Sorangium cellulosum Strain Soce375. , 2016, Journal of natural products.

[4]  R. Müller,et al.  Pyrronazols, metabolites from the myxobacteria Nannocystis pusilla and N. exedens, are unusual chlorinated pyrone-oxazole-pyrroles. , 2014, Journal of natural products.

[5]  J. Dubuisson,et al.  Hepatitis C Virus and Natural Compounds: a New Antiviral Approach? , 2012, Viruses.

[6]  G. Bifulco,et al.  Aetheramides A and B, potent HIV-inhibitory depsipeptides from a myxobacterium of the new genus "Aetherobacter". , 2012, Organic letters.

[7]  David E. Williams,et al.  Bafilomycins produced in culture by Streptomyces spp. isolated from marine habitats are potent inhibitors of autophagy. , 2010, Journal of natural products.

[8]  M. Janicot,et al.  R176502, a new bafilolide metabolite with potent antiproliferative activity from a novel Micromonospora species. , 2003, The Journal of antibiotics.

[9]  H. Reichenbach,et al.  Argyrins, immunosuppressive cyclic peptides from myxobacteria. I. Production, isolation, physico-chemical and biological properties. , 2002, The Journal of antibiotics.

[10]  H. Reichenbach,et al.  Tubulysins, new cytostatic peptides from myxobacteria acting on microtubuli. Production, isolation, physico-chemical and biological properties. , 2000, The Journal of antibiotics.

[11]  H Irschik,et al.  The soraphens: a family of novel antifungal compounds from Sorangium cellulosum (Myxobacteria). I. Soraphen A1 alpha: fermentation, isolation, biological properties. , 1994, The Journal of antibiotics.

[12]  H. Reichenbach,et al.  Three New Potent HIV-1 Inhibitors from Myxobacteria , 1992 .

[13]  K. Altendorf,et al.  Bafilomycins: a class of inhibitors of membrane ATPases from microorganisms, animal cells, and plant cells. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[14]  H. Zähner,et al.  METABOLIC PRODUCTS OF MICROORGANISMS. 224 , 1984 .

[15]  M. Stadler,et al.  How to Overcome the Antibiotic Crisis , 2016, Current Topics in Microbiology and Immunology.

[16]  H. Reichenbach,et al.  Biologically active secondary metabolites from myxobacteria. , 1993, Biotechnology advances.

[17]  A. Slawin,et al.  A conformational study of bafilomycin A1 by x-ray crystallography and nmr techniques , 1987 .

[18]  K. Albert,et al.  The structure of the bafilomycins, a new group of macrolide antibiotics , 1983 .